Retatrutide + Tesamorelin + Ipamorelin
otherStacks & Combinations
Research status · Investigational
Combination is not FDA-approved. Retatrutide is investigational, tesamorelin is approved only for a specific HIV-lipodystrophy indication, and ipamorelin is not FDA-approved.
This triple combination is discussed in body-composition communities, combining a metabolic investigational drug with GH-axis agents. The combination has no standardized clinical role in Reta's current data.
How it works
The components target different pathways: retatrutide affects incretin/glucagon receptors; tesamorelin mimics GHRH; ipamorelin stimulates the growth-hormone secretagogue receptor.
Common components
Commonly discussed purpose
- Body-composition discussion
- Recovery, sleep, or visceral-fat discussion
Commonly discussed use cases
- Metabolic and body-composition discussion
- GH-axis monitoring discussion
Supposed / potential benefits
- No approved combined indication
- No Reta-verified evidence that this triple combination is safe or effective
Common side effects
- GI effects
- Hunger changes
- Fluid retention or tingling
- Glucose or IGF-1 changes
- Unknown additive risk
Warnings & contraindications
- Layering GH-axis agents can increase monitoring complexity
- Retatrutide and ipamorelin are not FDA-approved for routine prescription use
- This is educational information, not a suggested stack
Typical timing considerations
No established or recommended combined regimen. A clinician should review whether any component is appropriate at all.
Administration route
Subcutaneous injection
Questions to ask your clinician
- Is there any validated reason to combine two GH-axis agents?
- What IGF-1, glucose, and adverse-effect monitoring would be required?
- Are approved alternatives more appropriate for my goal?
Commonly tracked in Reta
Tracking fields organize user-entered, clinician-directed routines — Reta never recommends or computes doses.
Track this in Reta
Beta members get a ready-made tracker for Retatrutide + Tesamorelin + Ipamorelin — schedule, dose log, injection-site rotation, reminders, and check-ins — for organizing a clinician-directed routine. Personal tracking is available to everyone during the Public Beta.
Reta is a tracking and education tool — not a medical provider. Nothing here is a diagnosis, treatment, prescription, or dosing recommendation. Peptides and medications should only be used under the direction of a licensed clinician. Talk to a qualified clinician before starting, stopping, combining, or changing anything. Many compounds below are not FDA-approved for human use; some are investigational or sold through unregulated channels where purity and dosing are not guaranteed.